Novel Antibiotics At ICAAC Spur Optimism On Resistance Front
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.
You may also be interested in...
GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.
Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria
Three years after creating its RX-04 discovery platform, Rib-X Pharmaceuticals Inc. has vetted 1,400 compounds, tuned them for efficacy against multi-drug resistant bacteria, and is in the process of selecting a handful of candidates to prep for an IND in 2012.
Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria
Three years after creating its RX-04 discovery platform, Rib-X Pharmaceuticals Inc. has vetted 1,400 compounds, tuned them for efficacy against multi-drug resistant bacteria, and is in the process of selecting a handful of candidates to prep for an IND in 2012.